Cas:1028307-48-3 RH-34 manufacturer & supplier

We serve Chemical Name:RH-34 CAS:1028307-48-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

RH-34

Chemical Name:RH-34
CAS.NO:1028307-48-3
Synonyms:MFCD22573566;2,4(1H,3H)-Quinazolinedione, 3-[2-[[(2-methoxyphenyl)methyl]amino]ethyl]-;qcr-286;3-{2-[(2-Methoxybenzyl)amino]ethyl}-2,4(1H,3H)-quinazolinedione;RH-34
Molecular Formula:C18H19N3O3
Molecular Weight:325.362
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.2±0.1 g/cm3
Index of Refraction:1.595
PSA:76.38000
Exact Mass:325.142639
LogP:2.48

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like MFCD22573566 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,RH-34 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,RH-34 Use and application,RH-34 technical grade,usp/ep/jp grade.


Related News: FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. RH-34 manufacturer Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding. RH-34 supplier Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management, Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said. RH-34 vendor Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. RH-34 factory FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus.